IN2014MN00988A - - Google Patents
Info
- Publication number
- IN2014MN00988A IN2014MN00988A IN988MUN2014A IN2014MN00988A IN 2014MN00988 A IN2014MN00988 A IN 2014MN00988A IN 988MUN2014 A IN988MUN2014 A IN 988MUN2014A IN 2014MN00988 A IN2014MN00988 A IN 2014MN00988A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- cancer
- diseases
- processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552880P | 2011-10-28 | 2011-10-28 | |
GBGB1118652.5A GB201118652D0 (en) | 2011-10-28 | 2011-10-28 | New compounds |
PCT/GB2012/052666 WO2013061074A1 (en) | 2011-10-28 | 2012-10-26 | Quinolines as fgfr kinase modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN00988A true IN2014MN00988A (ja) | 2015-04-24 |
Family
ID=45373580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN988MUN2014 IN2014MN00988A (ja) | 2011-10-28 | 2012-10-26 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9439896B2 (ja) |
EP (1) | EP2776397B1 (ja) |
JP (1) | JP6067725B2 (ja) |
KR (1) | KR102072869B1 (ja) |
CN (1) | CN104011025B (ja) |
AU (1) | AU2012328164B2 (ja) |
BR (1) | BR112014010177B1 (ja) |
CA (1) | CA2853366C (ja) |
DK (1) | DK2776397T3 (ja) |
ES (1) | ES2661003T3 (ja) |
GB (1) | GB201118652D0 (ja) |
HU (1) | HUE037458T2 (ja) |
IN (1) | IN2014MN00988A (ja) |
MX (1) | MX353806B (ja) |
RU (1) | RU2625303C2 (ja) |
WO (1) | WO2013061074A1 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
EP2909193B1 (en) | 2012-10-16 | 2017-04-19 | Janssen Pharmaceutica NV | Phenyl linked quinolinyl modulators of ror-gamma-t |
EP2909189B8 (en) | 2012-10-16 | 2017-04-19 | Janssen Pharmaceutica NV | Heteroaryl linked quinolinyl modulators of ror-gamma-t |
WO2014062658A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
WO2015057206A1 (en) * | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9346782B2 (en) * | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
AU2014334616A1 (en) * | 2013-10-15 | 2016-04-28 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORyt |
KR102479693B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | 조합물 |
WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
MX369646B (es) | 2014-08-18 | 2019-11-15 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monociclico y su cristal. |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
RU2747644C2 (ru) * | 2015-09-23 | 2021-05-11 | Янссен Фармацевтика Нв | Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака |
KR20180052623A (ko) | 2015-09-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | 신규 화합물 |
CN108264510A (zh) * | 2017-01-02 | 2018-07-10 | 上海喆邺生物科技有限公司 | 一种选择性抑制激酶化合物及其用途 |
JPWO2019189241A1 (ja) | 2018-03-28 | 2021-03-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
CN113087696A (zh) * | 2019-12-23 | 2021-07-09 | 江苏开元药业有限公司 | 喹啉类化合物及其应用 |
EP4076449A4 (en) * | 2020-01-17 | 2023-12-06 | Beta Pharma, Inc. | PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES USED AS FGFR KINASE INHIBITORS |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
EP0763537A3 (en) | 1993-05-14 | 1997-10-22 | Genentech Inc | Non-peptides farnesyl transfer inhibitors |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
CA2291750A1 (en) | 1997-05-28 | 1998-12-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
US7169778B2 (en) | 1999-09-15 | 2007-01-30 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
JP4286146B2 (ja) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤 |
UA82058C2 (uk) | 2001-12-24 | 2008-03-11 | Астразенека Аб | Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі |
JP2003213463A (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 |
US7223738B2 (en) | 2002-04-08 | 2007-05-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
US20040097725A1 (en) | 2002-07-10 | 2004-05-20 | Norman Herron | Charge transport compositions and electronic devices made with such compositions |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
BR0315053A (pt) | 2002-10-03 | 2005-08-09 | Targegen Inc | Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos |
AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
DE502004008322D1 (de) | 2003-05-23 | 2008-12-04 | Aterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
EP1646383A4 (en) | 2003-07-21 | 2009-03-25 | Bethesda Pharmaceuticals Inc | DESIGN AND SYNTHESIS OF LIGANDS OPTIMIZED FOR PPAR |
EP1651631A1 (en) | 2003-08-01 | 2006-05-03 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against flaviviridae |
ATE369862T1 (de) | 2003-10-17 | 2007-09-15 | 4 Aza Ip Nv | Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie |
WO2005046589A2 (en) | 2003-11-07 | 2005-05-26 | Chiron Corporation | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
MY154363A (en) * | 2003-11-20 | 2015-06-15 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors |
EA009875B1 (ru) * | 2003-11-20 | 2008-04-28 | Янссен Фармацевтика Н.В. | 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы |
RU2377241C2 (ru) | 2003-11-24 | 2009-12-27 | Ф.Хоффманн-Ля Рош Аг | Производные пиразоло-имидазопиримидина, обладающие антагонистической активностью в отношении кортикотропин-рилизинг фактора (crf) |
PL1706385T3 (pl) | 2003-12-23 | 2011-03-31 | Astex Therapeutics Ltd | Pochodne pirazolu jako modulatory kinazy białkowej |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
EP1789399A1 (en) | 2004-08-31 | 2007-05-30 | AstraZeneca AB | Quinazolinone derivatives and their use as b-raf inhibitors |
KR100875408B1 (ko) | 2004-10-14 | 2008-12-23 | 에프. 호프만-라 로슈 아게 | Cdk1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논 |
PT1830869E (pt) | 2004-12-24 | 2013-08-22 | Spinifex Pharm Pty Ltd | Método de tratamento ou profilaxia |
NZ556686A (en) | 2005-02-14 | 2010-01-29 | Bionomics Ltd | Novel tubulin polymerisation inhibitors |
WO2006092430A1 (de) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
WO2006124354A2 (en) | 2005-05-12 | 2006-11-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
CN101223170A (zh) | 2005-05-18 | 2008-07-16 | 惠氏公司 | Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法 |
GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
EP1917252B1 (en) | 2005-08-26 | 2014-01-01 | Merck Serono SA | Pyrazine derivatives and use as pi3k inhibitors |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
AU2006313701B2 (en) | 2005-11-11 | 2012-05-31 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
US8030305B2 (en) | 2005-12-21 | 2011-10-04 | Janssen Pharmaceutica N.V. | Triazolopyridazines as kinase modulators |
EP2024342A2 (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
JP2009537590A (ja) | 2006-05-24 | 2009-10-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四員複素環で置換された置換プテリジン |
US20100016293A1 (en) | 2006-07-03 | 2010-01-21 | Rogier Adriaan Smits | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use |
JP2008127446A (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | 1,5−ナフチリジン化合物及び有機発光素子 |
JP2010513278A (ja) | 2006-12-13 | 2010-04-30 | シェーリング コーポレイション | Igf1rインヒビターを用いた癌の処置方法 |
CN101641351A (zh) | 2006-12-21 | 2010-02-03 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
US20100216767A1 (en) | 2006-12-22 | 2010-08-26 | Mina Aikawa | Quinazolines for pdk1 inhibition |
CA2672172C (en) | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
JP2010526823A (ja) | 2007-05-10 | 2010-08-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのキノキサリン誘導体 |
EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
KR101251933B1 (ko) | 2007-06-20 | 2013-04-09 | 미쓰비시 타나베 파마 코퍼레이션 | 신규한 말론산술폰아미드 유도체 및 그 의약 용도 |
US8629144B2 (en) | 2007-06-21 | 2014-01-14 | Janssen Pharmaceutica Nv | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
WO2009021083A1 (en) | 2007-08-09 | 2009-02-12 | Smithkline Beecham Corporation | Quinoxaline derivatives as pi3 kinase inhibitors |
US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
NZ585139A (en) | 2007-11-16 | 2012-05-25 | Incyte Corp | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as jak inhibitors |
MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
EP2282995B1 (en) | 2008-05-23 | 2015-08-26 | Novartis AG | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
JP2012509342A (ja) | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ[2,3−b]−ピリジンおよび−ピラジン |
JP5662346B2 (ja) | 2009-01-21 | 2015-01-28 | バジリア ファルマスーチカ アーゲーBasilea Pharmaceutica AG | 新規二環式抗生物質 |
EP2391623A4 (en) | 2009-02-02 | 2012-09-05 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2010143169A2 (en) * | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
EA021275B9 (ru) | 2009-09-03 | 2015-08-31 | Байоэнердженикс | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания |
CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
EP2560966B1 (en) | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
JP5894980B2 (ja) | 2010-05-24 | 2016-03-30 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
CN102532141A (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1,2,4]***并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途 |
CN103476777B (zh) | 2011-01-31 | 2015-05-27 | 诺瓦提斯公司 | 新杂环衍生物 |
AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
WO2013032951A1 (en) | 2011-08-26 | 2013-03-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
EP2755657B1 (en) | 2011-09-14 | 2017-11-29 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
US20140235643A1 (en) | 2011-10-04 | 2014-08-21 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
PL2771342T3 (pl) | 2011-10-28 | 2016-11-30 | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób | |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
CA2865388C (en) | 2012-03-08 | 2022-01-04 | Astellas Pharma Inc. | Novel fgfr3 fusion |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
US9221804B2 (en) * | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
KR102479693B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | 조합물 |
WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
-
2011
- 2011-10-28 GB GBGB1118652.5A patent/GB201118652D0/en not_active Ceased
-
2012
- 2012-10-26 AU AU2012328164A patent/AU2012328164B2/en active Active
- 2012-10-26 ES ES12794744.8T patent/ES2661003T3/es active Active
- 2012-10-26 JP JP2014537724A patent/JP6067725B2/ja active Active
- 2012-10-26 WO PCT/GB2012/052666 patent/WO2013061074A1/en active Application Filing
- 2012-10-26 MX MX2014004857A patent/MX353806B/es active IP Right Grant
- 2012-10-26 KR KR1020147010839A patent/KR102072869B1/ko active IP Right Grant
- 2012-10-26 DK DK12794744.8T patent/DK2776397T3/en active
- 2012-10-26 HU HUE12794744A patent/HUE037458T2/hu unknown
- 2012-10-26 CA CA2853366A patent/CA2853366C/en active Active
- 2012-10-26 RU RU2014121494A patent/RU2625303C2/ru active
- 2012-10-26 CN CN201280065182.XA patent/CN104011025B/zh active Active
- 2012-10-26 IN IN988MUN2014 patent/IN2014MN00988A/en unknown
- 2012-10-26 EP EP12794744.8A patent/EP2776397B1/en active Active
- 2012-10-26 US US14/354,773 patent/US9439896B2/en active Active
- 2012-10-26 BR BR112014010177-9A patent/BR112014010177B1/pt active IP Right Grant
-
2016
- 2016-07-08 US US15/205,676 patent/US10039759B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014530896A (ja) | 2014-11-20 |
BR112014010177B1 (pt) | 2023-01-31 |
US20170000781A1 (en) | 2017-01-05 |
JP6067725B2 (ja) | 2017-01-25 |
MX353806B (es) | 2018-01-30 |
US10039759B2 (en) | 2018-08-07 |
WO2013061074A1 (en) | 2013-05-02 |
EP2776397A1 (en) | 2014-09-17 |
DK2776397T3 (en) | 2018-02-26 |
US9439896B2 (en) | 2016-09-13 |
CA2853366A1 (en) | 2013-05-02 |
AU2012328164A1 (en) | 2014-05-15 |
CN104011025A (zh) | 2014-08-27 |
KR102072869B1 (ko) | 2020-03-02 |
CA2853366C (en) | 2021-04-20 |
EP2776397B1 (en) | 2017-11-29 |
MX2014004857A (es) | 2014-08-26 |
RU2625303C2 (ru) | 2017-07-13 |
GB201118652D0 (en) | 2011-12-07 |
ES2661003T3 (es) | 2018-03-27 |
AU2012328164B2 (en) | 2017-08-03 |
HUE037458T2 (hu) | 2018-09-28 |
RU2014121494A (ru) | 2015-12-10 |
KR20140093665A (ko) | 2014-07-28 |
US20140296236A1 (en) | 2014-10-02 |
CN104011025B (zh) | 2017-04-05 |
BR112014010177A2 (pt) | 2017-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN00988A (ja) | ||
IN2014MN00986A (ja) | ||
IN2014MN00987A (ja) | ||
IN2014MN00948A (ja) | ||
IN2012MN02591A (ja) | ||
IN2014MN02069A (ja) | ||
IN2014MN02049A (ja) | ||
PH12015501385A1 (en) | Autotaxin inhibitors | |
PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
IN2014KN02601A (ja) | ||
MX343706B (es) | Derivados heterocíclicos novedosos. | |
IN2015DN01119A (ja) | ||
IN2015DN01151A (ja) | ||
IN2014MN00697A (ja) | ||
IN2013DN02555A (ja) | ||
IN2014DN03010A (ja) | ||
UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази | |
TN2013000327A1 (en) | Novel heterocyclic derivatives |